Is luteinizing hormone needed for optimal ovulation induction?

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 3, 2002, Pages 265-274

  Balasch, Juan ^a   Fábregues, Francisco ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT GONADOTROPIN; RECOMBINANT HORMONE; RECOMBINANT LUTEINIZING HORMONE; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; DRUG EFFECT; FEMALE; FEMALE INFERTILITY; HORMONAL THERAPY; HORMONE ACTION; HUMAN; INFERTILITY THERAPY; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PRIORITY JOURNAL; REVIEW;

FEMALE; HUMANS; INFERTILITY, FEMALE; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OVULATION INDUCTION; PREGNANCY; RECOMBINANT PROTEINS;

EID: 0036265336     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200206000-00004     Document Type: Review

References (39)

1. Gonadotropic control of ovarian follicular growth and development
2. Controlled ovarian stimulation in women
3. Ovarian paracrine signalling and ovulation induction
4. Effects of different menotropin preparations for assisted reproduction in hypogonadotropic hypogonadism
5. Inducing follicular development in anovulatory patients and normally ovulating women: Current concepts and the role of recombinant gonadotropins
6. Roles and novel regimens of luteinizing hormone and follicle-stimulating hormone in ovulation induction
7. The role of luteinizing hormone in human follicle development and oocyte fertility: Evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone
8. Are estrogens of import to primate/human ovarian folliculogenesis?
9. Suppression of LH during ovarian stimulation: Effects differ in cycles stimulated with purified urinary FSH and recombinant FSH
10. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction
11. Suppression of LH during ovarian stimulation: Analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH
12. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process
13. Adverse effects of luteinizing hormone on fertility: Fact or fantasy
14. Gonadotrophin-releasing hormone analogue as an adjunct to gonadotrophin therapy for clomiphene-resistant polycystic ovarian syndrome
15. Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles
16. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: A dose finding study
17. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: Evidence from a multicentre study in Spain
18. Roles of follicle stimulating hormone and luteinizing hormone in controlled ovarian hyperstimulation
19. Do all women need LH for ovarian stimulation?
20. Optimal levels of LH, or not enough power to say
21. Optimal levels of LH, or not enough power to say
22. Optimal levels of LH, or not enough power to say
23. The potential value of mid-follicular LH
24. The potential value of mid-follicular LH
25. Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles
26. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles
27. Progress of ART: The role of the clinician
28. Recent trends in assisted reproductive techniques and associated outcomes
29. The effect of exogenous luteinizing hormone (LH) on oocyte viability: Evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction
30. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH
31. Exogenous luteinizing hormone (LH) increases estradiol response patterns in poor responders with low serum LH concentrations
32. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: A preliminary study
33. Embryo implantation and GnRH antagonists. Embryo implantation: The Rubicon for GnRH antagonists
34. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon)
35. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome
36. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): A role for LH in the final stages of follicular maturation
37. A protease-resistant prion protein isoform is present in urine of animals and humans affected with prion diseases